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Abstract 
Current expressions based on serum creatinine concentration overestimate 
kidney function in cirrhosis leading to significant differences between “true” 
and calculated glomerular filtration rate (GFR). We compared the performance 
of MDRD-4, MDRD-6 and CKD-EPI with “true” GFR and the impact of this 
difference on MELD calculation. We subsequently developed and validated a 
GFR equation specifically for cirrhosis and compared the performance of the 
new derived formula with existing GFR formulas. We included 469 
consecutive patients who had a transplant assessment between 2011 and 
2014. “True” GFR (mGFR) was measured using plasma isotope clearance 
according to a technique validated in patients with ascites. A corrected 
creatinine was derived from the mGFR after application of the MDRD formula. 
Subsequently, a corrected MELD was calculated and was compared with the 
conventionally calculated MELD. Stepwise multiple linear regression was 
used to derive a GFR equation. This was compared with the measured GFR 
in independent external and internal validation sets of 82 and 174 patients 
with cirrhosis respectively. A difference>20 ml/min/1.73m2 between existing 
formulae and mGFR was observed in 226 (48.2%) patients. The corrected 
MELD score was ≥3 points higher in 177 (37.7%) patients.  The predicted 
equation derived (R2=746%) was: GFR=459x(creatinine-0836)x(urea-
0229)x(INR-0113)x(age0129)x(sodium0972)x1236(if male)x092(if 
moderate/severe ascites). The model was a good fit and showed the greatest 
accuracy compared to that of existing formulae.  Conclusion: We developed 
and validated a new accurate model for GFR assessment in cirrhosis, the 
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RFH cirrhosis GFR, using readily available variables. This remains to be 
tested and incorporated in prognostic scores in patients with cirrhosis. 
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Kidney dysfunction is a common finding in patients with cirrhosis and is 
associated with increased mortality (1, 2). This is reflected by the inclusion of 
serum creatinine concentration in the Model for End-stage Liver Disease 
(MELD) score, which is a prognostic tool used for liver transplant prioritization. 
However, the use of creatinine for kidney function assessment in patients with 
cirrhosis can lead to systematic bias. Decreased creatinine production, 
increased tubular creatinine excretion, muscle depletion and the interference 
of high bilirubin levels with the analytic methods used for determination of 
creatinine (especially with the Jaffe reaction) may contribute to falsely low 
serum creatinine levels, thus leading to an overestimation of kidney function 
and an underestimation of liver disease severity using the MELD score (3).  
 Accurate measurement of GFR is particularly challenging in patients 
with liver disease and there is not a clear consensus as to which technique is 
the best reference standard. Although plasma clearance methods for 
assessment of GFR are recommended, because of technical difficulties, lack 
of availability and high cost, these are not readily available to use in routine 
clinical practice. Furthermore, they are prone to inaccuracy, particularly in 
patients with fluid retention such as ascites (4). The current BNMS Guidelines 
for the measurement of GFR using plasma sampling recommend not to use 
plasma clearance assessment of GFR in patients with ascites, oedema or 
other expanded body space (5). Recently, however, Wickham et al have 
described a modified plasma clearance method for assessment of GFR that 
can be used in liver patients with ascites (6, 7). For liver transplant candidates 
without ascites, this method showed good agreement with the “slope 
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intercept” technique described in the current guidelines with plasma samples 
taken at 2, 4 and 6 hours post injection. 
 The creatinine-based equations used for estimation of GFR, which did 
not include patients with cirrhosis when first developed, are poor predictors of 
kidney function in patients with cirrhosis leading to a higher than 20% 
overestimation of “true” GFR (8, 9).  
 The primary objective of this study was to develop and validate a GFR 
equation specifically for patients with cirrhosis, and to compare the 
performance of the new derived formula with the existing GFR formulae of 4-, 
6-variable Modification of Diet in Renal Disease (MDRD) and Chronic Kidney 
Disease-Epidemiology (CKD-EPI). Secondary objectives were to assess the 
differences between measured and estimated GFR using common GFR 
formulae and between observed and “corrected” MELD score and to evaluate 
the predictors of these differences.  
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PATIENTS AND METHODS  
 From January 2011 to September 2014, 469 consecutive patients with 
cirrhosis evaluated for liver transplantation at the Royal Free Hospital were 
included in the study and comprised the training dataset. An independent 
cohort of consecutive patients with cirrhosis (n=82) with available crEDTA and 
cystatin measurements that were evaluated in Hippokration General Hospital 
of Thessaloniki in Greece was included as an external validation set. The 
internal validation set included 174 patients with cirrhosis assessed for a liver 
transplant between February 2007 and December 2010. The GFR 
measurement using isotope plasma clearance was part of the patients’ 
standard pre-transplant work-up. An independent cohort of consecutive 
patients with cirrhosis (n=82) with available crEDTA and cystatin 
measurements that were evaluated in Hippokration General Hospital of 
Thessaloniki in Greece was included as an external validation set. Patients 
with simultaneous multiple organ transplantation, acute liver failure or prior 
liver transplantation were excluded from the analysis. The Royal Free Hospital 
Institutional Review Board approved the study prior to data collection. The 
study protocol conformed to the ethical guidelines of the 1975 Declaration of 
Helsinki. 
Creatinine Assessment 
 Creatinine concentration was measured in each sample using the 
O’Leary modified Jaffe method which shows the least interference with 
bilirubin levels (10). Creatinine measurements were measured on the Roche 
Analyser using Roche reagents in the Royal Free Hospital (Roche Diagnostics 
GmbH, Sanhofer Strasse 116, D-68305, Manheim). In the external validation 
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cohort, compensated Jaffe was used for creatinine measurements (Beckman  
Coulter  CA  92821,  USA)  and  cystatin C  was  analyzed  by 
immunonephelometry using a BN-ProSpec analyzer (Dade Behring BN-
ProSpec) (reference range:  0.53  to  0.95  mg/L). All creatinine 
measurements performed were standardized to IDMS Standards.  
Glomerular Filtration Rate Assessment using radioisotope plasma 
clearance 
 For patients in the training and internal validation dataset, assessment 
of GFR using radioisotope plasma clearance was carried out as previously 
described (6, 7). For patients in the external validation set assessment of GFR 
was performed as recently described (11). Full details are provided in the 
Appendix.  
Formulae for Glomerular Filtration Rate Estimation 
 All formulas were calculated according to published data (12-14). 
Details are provided in the Appendix.  
Statistical Analysis 
Descriptive analysis 
 The MDRD study equation was rearranged to give an expression for 
creatinine concentration in terms of GFR. This expression was used to 
calculate a value for corrected creatinine concentration from mGFR. 
Subsequently, a corrected MELD was calculated. Wilcoxon signed rank test 
was used to assess the differences between corrected and observed MELD 
scores. Full details are given in the Web Appendix.  
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Derivation and validation of the new equation for GFR estimation 
 Backward stepwise multiple linear regression on log-transformed data 
was used to derive a new GFR equation by using the training set. The SPSS 
default p values for removing or re-entering variables were used. Data were 
logarithmically transformed to eliminate the great variance across the range of 
GFR, and were subsequently re-expressed in their original units (12, 15). The 
following variables were considered in the univariate analysis: age, sex, 
ethnicity, mean arterial pressure, dry weight, height, body mass index, hand 
grip strength, INR, serum albumin, urea, creatinine, total bilirubin and sodium 
levels, presence and severity of ascites and encephalopathy, etiology of liver 
disease, MELD and CP scores (12, 15).  
 The regression coefficients determined in the training set were applied 
to obtain the predicted GFRs in the validation set. To determine if the new 
equation fits the data well, we calculated R2 statistic, the mean difference 
between observed and predicted GFR (residual) values in the validation set, 
the root mean square error (standard deviation of the mean difference) and 
the appropriate residual plots.  
Performance and comparison of the different equations to predict 
glomerular filtration rate in the training and validation set 
 Bias was assessed as the median difference between mGFR and 
estimated GFR using the new equation, MDRD and CKD-EPI study equations 
with negative values indicating an overestimation of mGFR (12). Precision 
was assessed as interquartile range (IQR) for the differences (12). Accuracy 
was assessed as the percentage of predictions within 10% (P10), 30% (P30) 
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and 50% (P50) of mGFR (8). Confidence intervals of median difference, IQR 
and P10, P30 and P50 were estimated with the bootstrap method (200 
bootstraps). Significance testing was two-sided and set to <005. Analysis 
was performed using the SPSS statistical package (version 22.0, IBM, New 
York, NY, USA) and the MedCalc for Windows (version 12.5, MedCalc 
Software, Ostend, Belgium). 
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RESULTS 
Demographic and clinical characteristics 
 The baseline patients’ characteristics in the training and validation 
cohorts are shown in Table 1. There were significant differences in urea, 
albumin, sodium and mGFR levels, as well as in the prevalence of ascites and 
encephalopathy.  
Difference between mGFR and estimated GFR 
 For the training dataset the median difference between estimated GFR 
and mGFR was 191 (IQR: 241) and 199 (IQR: 227) ml/minute/173 m2 for 
MDRD and CKD-EPI formulae, respectively. Plots of estimated GFR versus 
the difference between measured GFR and estimated GFR showed a 
consistent overestimation of GFR when using these formulas (Figure 1a-c and 
Appendix Figure 1a,b).  
 A difference >20 ml/min/173 m2 between MDRD and mGFR was 
observed in 226 (48.2%) patients. In multivariate binary logistic regression 
analysis, this difference was independently associated with male sex (odds 
ratio (OR):  35, 95% Confidence Interval (CI):  212-58), moderate/severe 
ascites (OR: 21, 95%CI: 131-338), and serum levels of sodium (OR: 0919, 
95%CI: 0873-0967), creatinine (OR: 0949, 95%CI: 0937-0961) and 
bilirubin (OR: 1003, 95%CI: 1001-1005). The difference was more 
pronounced in patients with worsening Child Pugh class (Appendix Table 1). 
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MELD score using “corrected” creatinine levels 
 The median “corrected” MELD was 14 (range 6-37) and was 
significantly higher than the observed median MELD score (11, range 6-61) 
(Wilcoxon test: z= -733, p<0001). The corrected MELD score was ≥3 points 
higher in 177 (377%) patients. In the multivariate binary regression analysis, 
the factors significantly associated with a difference ≥3 points were: high 
Child-Pugh score (OR: 1528, 95%CI: 1367-1708) and low creatinine levels 
(OR: 098, 95%CI: 097-0988). The proportion of patients with ≥3 difference 
increased along with the severity of liver disease (Child-Pugh A vs. B vs. C: 
19 (165%) vs. 88 (364%) vs. 70 (625%), respectively; p<0001). 
Prediction of glomerular filtration rate from stepwise regression analysis 
  The variables that were finally included in the multivariate stepwise 
regression model to estimate log mGFR were: log-transformed serum 
creatinine, urea, INR, age, sodium, bilirubin, albumin, BMI, ethnicity, sex, 
mild/moderate/severe encephalopathy, and moderate/severe ascites (Table 
2).  
 The derived equation with the maximal R2 (746%) was:  
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We have named this equation the “Royal Free Hospital (RFH) Cirrhosis GFR”. 
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 Subsequently, this model was applied to the internal validation set to 
obtain predicted GFR values. The mean difference between observed and 
predicted GFR (residual) values in the validation set was 38 ml/min/173 m2 
with a root mean square error of 148. According to the residual plots the 
model was a good fit (Figure 2, Appendix Figure 2).   
Performance of the new equation, MDRD, CG and CKD EPI formulae 
Table 3 shows the performance of RFH cirrhosis GFR compared with the 
performances of 4-, 6-variable MDRD and CKD EPI to predict mGFR in both 
the external and internal validation datasets. The new equation showed the 
highest performance, followed by MDRD and CKD-EPI study equations. Plot 
analysis in the validation groups showed that the new model had greater 
accuracy than all others formulaes to predict mGFR (Figure 2 and 3, Appendix 
Figure 1d).  To further evaluate the accuracy of the new equation, we 
calculated the percentage of the predicted GFR with the different formulae 
within the 10%, 30% and 50% of mGFR (P10, P30 and P50) in both cohorts. 
As shown in Table 3, the new equation had the highest accuracy, with P10, 
P30 and P50 values of 56.1%, 89% and 98.8% in the external validation and 
454%, 885% and 966% in the internal validation cohort respectively. The 
performance of the new equation was not influenced by either mGFR or 
degree of liver dysfunction (Appendix Table 1 and 2). Although the RFH 
cirrhosis GFR had better overall accuracy when compared with the cystatin C 
based equations, this result should be interpreted with caution as the cystatin 
C assay was not traceable to IFCC standards and this could explain the 
observed overestimate. 
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DISCUSSION 
 We developed and validated the RFH Cirrhosis GFR to predict GFR in 
patients with cirrhosis using data from consecutive patients awaiting liver 
transplantation. This equation was validated in independent cohorts of 
patients and showed higher accuracy and less bias than the existing GFR 
formulae. This is of critical importance because of the shortcomings of the 
equations based on serum creatinine concentration which are currently used 
for estimating kidney function in patients with cirrhosis (16). 
Levey et al (12, 15) used urinary clearance of iothalamate for reference 
measurements of GFR in the derivation of the Modification of Diet in Renal 
Disease (4-variable MDRD) and Chronic Kidney Disease Epidemiology (CKD-
EPI) study equations, but Kwong et al (19) have highlighted the limitations 
associated with the use of this technique caused by inaccuracies in 
measurement of urine volumes and times, iothalamate concentration and 
incomplete bladder emptying and physiologic day-to-day and diurnal 
fluctuation in GFR. All these emphasize the importance of the new GFR 
equation, which is specifically developed and validated in patients with 
cirrhosis, and takes into consideration potential variables that affect kidney 
function in this setting, together with known predictors of GFR such as age 
and sex.  
 The MDRD and CKD-EPI study equations systematically overestimated 
kidney function and this was more pronounced in patients with worse liver 
function. Indicatively, the difference between MDRD and the true GFR was 
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greater than 20 ml/min/173 m2 in approximately 50% of patients with 
cirrhosis. A similar discrepancy was observed using the CKD-EPI expressions 
(data not shown). As shown in the multivariate analysis, patients with higher 
bilirubin levels and lower serum sodium, and, thus, more impaired liver 
function, were more likely to have an overestimation of kidney function using 
the MDRD formula. Male sex was also independently associated with such a 
difference; therefore, male patients are disadvantaged using the MDRD 
formula, implying that the regression coefficient used for gender in the MDRD 
equation is inappropriate when used in cirrhosis. Presence of ascites also 
resulted to higher rates of overestimating true GFR; this is in line with the 
results by Francoz et al (9), who showed that 46% of 157 patients with 
cirrhosis had a GFR overestimation of ≥ 20% with the MDRD study equation. 
Finally, patients with lower creatinine levels are more likely to have an 
overestimation of GFR when using the MDRD study equation.  This reflects 
the already discussed discrepancies between measured creatinine and renal 
function in cirrhosis that are more profound in patients with creatinine 
concentrations within the normal range (9). Therefore, a number of patients 
with impaired kidney function (low GFR) and, thus, at a higher mortality risk 
but with low serum creatinine are significantly over-scored with the existing 
equations for GFR calculation.  
 The inaccuracy of creatinine in predicting kidney function and, 
subsequently, mortality in cirrhosis is reflected by the large proportion of 
patients (40%) with ≥3 points difference between the observed and 
“corrected” MELD score. This has major implications in the current liver 
transplant allocation system, with some patients being systematically 
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underscored, especially those with advanced liver disease and lower 
measured creatinine levels. Cholongitas et al (20) showed that this difference 
was more profound in female candidates for liver transplantation suggesting a 
3-point correction factor in females with MELD score higher than 19.  
 Gender and age, which are considered significant determinants of 
serum creatinine (21) as a result of their correlation with muscle mass, were 
independent predictors of GFR and were included into the new equation, 
similarly to existing GFR formulae. Patients with cirrhosis are commonly 
malnourished and/or sarcopenic (22) and, thus, the reduced muscle mass has 
a different impact on creatinine generation than that observed in the general 
population. Females have lower creatinine levels for the same GFR values 
compared to male patients with cirrhosis (20); therefore, gender was included 
in the new equation but with a different weight than the one used for GFR 
estimation in the other creatinine-based formulae. Urea was also an 
independent predictor of GFR reflecting the correlation between urea 
clearance and GFR; there is a difference in the ratios of the amount secreted 
by the tubule to the amount filtered by the glomerulus between urea and 
creatinine and, thus, although both are determinants of renal function, their 
serum levels fluctuate independently. In cirrhosis, circulating blood urea 
nitrogen might be increased as a result of occult gastrointestinal bleeding due 
to portal hypertensive gastropathy or use of steroids. Race did not have an 
impact on kidney function in patients with cirrhosis. Although this might be a 
type 2 error due to the low number of patients of black ancestry in our cohort, 
it seems that the weight given to race by the other creatinine-based equations 
is unsuitable for patients with cirrhosis compared to the general population or 
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to patients with chronic kidney insufficiency. On the other hand, the presence 
of moderate/severe ascites together with high INR values and low sodium 
levels had a negative correlation with GFR estimation, reflecting the impaired 
kidney function that accompanies patients with large-volume ascites and/or 
advanced liver disease (23, 24) due to the chronically reduced renal blood 
flow (25).  
  The accuracy of the new equation was satisfactory, and significantly 
better than the accuracy of existing formulae (89% vs. 27-75% of estimates 
being within 30% of true GFR respectively). The accuracy of existing formulae 
in our cohort is in agreement with previous reports (8) that showed that only 
60-66% of estimates (using CG, MDRD-4, -5, -6 variables and the Nankivell 
formulae) were within 30% of the measured GFR in a large cohort of 1147 
patients with cirrhosis. Precision, measured by the interquartile range for the 
differences, did not differ among the currently used formulae and is similar to 
that reported by Levey et all in the CKD-EPI prediction equation study (12).  
 The new equation, apart from being significantly more accurate, has 
several other advantages over the existing equations in patients with liver 
disease. Firstly, it was derived from a cohort of patients with cirrhosis at 
various stages of disease severity (MELD ranging from 6 to 44), including 
patients with hepatocellular carcinoma, and has been further validated in an 
independent cohort comprised of patients with diverse clinical characteristics. 
Secondly, it can be easily implemented in routine clinical practice as it 
includes readily available variables. Thirdly, it does not include variables such 
as albumin and bilirubin that can be influenced by several factors such as 
albumin infusions or require calibration in different laboratories for optimal use 
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(26). Lastly, it predicts GFR across a wide range of values allowing general 
applicability in patients with cirrhosis.  
 The main limitation of the new equation is the use of creatinine as the 
major determinant of glomerular filtration rate, which is influenced by several 
factors unrelated to kidney function; however, creatinine is the most readily 
available predictor of renal function and we tried to eliminate its weaknesses 
by including in the model other extra-renal determinants of renal function such 
age, gender and liver disease severity. The equations based on cystatin C, a 
protein that is eliminated almost exclusively by glomerular filtration, have 
better performance than the creatinine-based equations in patients with 
cirrhosis (27). However, the use of cystatin C is not without limitations 
including the high cost, its interference with several drugs such as steroids, 
the lack of standardization and its unsuitability in infectious conditions which 
are very common in end-stage liver disease (16). In an exploratory analysis, 
the RFH cirrhosis GFR equation performed better than cystatin C-based 
equations in the external validation cohort, but this needs to be further 
validated in larger series. Secondly, the prediction equation has been applied 
in a small proportion of black patients (6%) and only in the pre-transplant 
setting; therefore, this will need further validation in non-Caucasian 
populations.  Finally, although the sample sizes of the training and validation 
cohort are relatively small compared to other validation studies of estimating 
equations in the general population (12, 15), it is considerably larger than 
previous studies evaluating kidney function in cirrhosis and the findings were 
quite robust (28).  
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 In conclusion, inaccurate estimation of kidney function has major 
implications both in terms of prognosis but also in terms of candidate selection 
and prioritization for liver transplantation. We therefore developed and 
validated an accurate cirrhosis-specific equation for indirect GFR assessment 
in patients with varying disease severity, taking into consideration the most 
important renal and extra-renal determinants of renal function in cirrhosis. The 
Royal Free Hospital Cirrhosis GFR performs significantly better than existing 
equations such as MDRD and CKD-EPI. We strongly encourage other 
research teams to independently validate the performance of this equation in 
larger populations of patients with cirrhosis and diverse clinical characteristics. 
The incorporation of this cirrhosis-specific GFR equation instead of creatinine 
in prognostic scores such as MELD should be further tested, as it is highly 
likely that it will increase their overall performance. 
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Figure Legends 
Figure 1 Plots of estimated Glomerular Filtration Rate (eGFR) versus the 
difference between measured GFR (mGFR) and eGFR for a) MDRD-4, b) 
MDRD-6 and c) CKD-EPI in the validation dataset.  
Figure 2 In the scatter/dot plot of estimated Glomerular Filtration Rate (eGFR) 
versus the difference between measured GFR (mGFR) and eGFR for RFH 
cirrhosis GFR in the internal validation plot, the residuals appear to be 
randomly scattered about zero. The above plots show that the model fits the 
data well.   
Figure 3. Plot of estimated Glomerular Filtration Rate (eGFR) versus the 
difference between measured GFR (mGFR) and eGFR for RFH cirrhosis GFR 
in the external validation dataset.  
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Table 1 Baseline characteristics of the study population.  
 Training set 
(n=469) 
Internal 
Validation set 
(n=174) 
External 
Validation set 
(n=82) 
P1 value* P2 value** 
Age (years), median (range) 55 (16-76) 54 (21-71) 53 (16-75) 0.540 0.551 
Sex (M/F), n (%) 324/145 
(69.1/30.9) 
117/57 
(67.2/32.8) 
60/22 
(73.2/26.8) 
0.411 0.457 
Black, n (%) 29 (6.2) 9 (5.2) 
 
0 0.471 0.021 
Etiology of liver 
disease, n (%) 
Alcohol 
Viral hepatitis 
PSC 
PBC 
NASH/Cryptogenic 
Alcohol and Viral 
142 (30.3) 
135 (28.8) 
51 (10.9) 
25 (5.3) 
54 (11.5) 
4 (0.9) 
37 (21.3) 
56 (32.2) 
25 (14.4) 
11 (6.3) 
13 (7.4) 
15 (8.6) 
24 (29.3) 
36 (43.9) 
9 (11) 
3 (3.7) 
10 (12.2) 
0 
0.137 0.073 
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Other 32 (6.8) 15 (14.1) 0 
HCC, n (%) 111 (23.7) 54 (31) 8 (9.8%) 0.070 0.005 
BMI (kg/m2), median (range) 26.9 (16.7-
49.1) 
26.5 (16.9-
47.7) 
25.6 (19.3-
46.1) 
0.725 0.195 
BSA (m2), mean±SD 1.9±0.3) 1.9±0.2 1.9±0.2 0.819 0.171 
HGS (kg), median (range) 24 (2-47) 26.5 (9.5-56) NA 0.060 NA 
MAP (mmHg), median (range) 83 (59-122) 83.3 (63-103) NA 0.197 NA 
INR, median (range) 1.3 (0.9-5.8) 1.4 (0.9-2.8) 1.3 (1.0-7.2) 0.429 0.686 
Albumin (mg/dl), median (range) 33 (16-49) 35 (18-52) 31 (16-45) 0.002 0.094 
Bilirubin (µmol/L), median (range) 37 (3-639) 36 (4-932) 33.1 (7-397) 0.675 0.720 
Sodium (mmol/L), median (range) 138 (113-147) 139 (120-149) 137 (117-145) 0.023 0.346 
Urea (mmol/L), median (range) 5.2 (1.4-31.1) 4.8 (1.8-26.2) 5.7 (2.2-36.4) 0.029 0.132 
Creatinine (µmol/L), median (range) 75 (33-464) 72 (39-261) 85.8 (43-261) 0.135 0.002 
Corrected creatinine (µmol/L), median 81.06 (11.1- NA NA 0.251 NA 
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(range) 162.5) 
Measured GFR (ml/minute/1.73 m2), 
median (range) 
66 (7-129) 78.1 (5.7-141) 73 (16-150) <0.001 0.048 
GFR MDRD-4 (ml/minute/1.73 m2), median 
(range) 
87.04 (9.7-
230.6) 
90.9 (18.9-
230.8) 
76.55 (23.08-
168.47) 
0.359 0.001 
GFR MDRD-6 (ml/minute/1.73 m2), median 
(range) 
81.63 (10.1-
193.9) 
85.2 (19.4-
178.1) 
NA 0.57 NA 
CKD-EPI (ml/minute/1.73 m2), median 
(range) 
93.6 (10.3-
158.7) 
95.0 (20.4-
156.4) 
85.0 (24.0-
145.0) 
0.203 0.002 
MELD score, median (range) 11 (6-44) 14 (6-37) 13 (5-48) 0.008 0.209 
CP score, median (range) 8 (5-13) 7 (5-15) 8 (5-13) <0.001 0.932 
CP class, n (%) A 115 (24.5) 
242 (51.6) 
112 (23.9) 
65 (37.4) 
75 (43.1) 
34 (19.5) 
19 (23.2) 0.004 0.932 
B 42 (51.2) 
C 21 (25.6) 
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Ascites, n (%) No/Mild 167 (35.6) 
182 (38.8) 
120 (25.6) 
122 (70.1) 
31 (17.8) 
21 (12.1) 
5 (6.1) <0.001 <0.001 
Moderate 47 (57.3) 
Severe 30 (36.6) 
Encephalopathy, n 
(%) 
No 388 (82.7) 
79 (16.8) 
2 (0.4) 
140 (80.5) 
29 (16.7) 
5 (2.9) 
64 (78.0) 0.046 0.456 
Mild/Moderate 18 (22.0) 
Severe 0 
PSC: primary sclerosing cholangitis, PBC: primary biliary cirrhosis, NASH: non-alcoholic steatohepatitis, HCC: hepatocellular carcinoma, BMI: Body Mass 
Index, BSA: Body Surface Area, HGS: hand grip strength, MAP: mean arterial pressure, INR: International Normalized Ratio, GFR: Glomerular Filtration 
Rate, MDRD: Modification of Diet in Renal Disease, CKD-EPI: (chronic kidney disease–epidemiology), MELD: Model for End-stage Liver Disease, CP: Child-
Pugh, NS: not significant, NA: not available 
* 
Training versus internal validation group   
**
 Training versus external validation group  
 
 
 
 
 
 
Table 2 Multiple regression model to predict glomerular filtration rate on the logarithmical scale.  
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Variables Coefficients 95% Confidence Interval (lower, higher) 
Quantitative 
Log Creatinine (µmol/L) -0.836 -0.920, -0.750 
Log Urea (mmol/L) -0.229 -0.293, -0.165 
Log INR  -0.113 -0.200, -0.023 
Log age (years) -0.129 -0.217, -0.042 
Log sodium (mmol/L) 0.972 0.320, 1.620 
Qualitative 
Sex (female) -0.092 -0.113, -0.072 
Moderate/Severe ascites -0.0369 -0.058, -0.015 
  
 
Table 3 Comparison of the performances of the new equation, MDRD and CKD-EPI equations in the training and external 
and internal validation cohorts.  
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 New equation MDRD-4 MDRD-6 CKD-EPI CKD-EPI 
cystatin C 
CKD-EPI 
cystatin C-
creatinine 
 Training cohort   
Median difference (95% 
CI), ml/minute/1.73 m2 
 -19.2 (-21.3, -
17.1) 
-13.0 (-15.1, -
11.4) 
-19.9 (-22.4, -
17.9) 
NA NA 
Interquartile Range for 
differences (95% CI), 
ml/minute/1.73 m2 
 24.1 (21.7, 
27.3) 
21.3 (18.2, 
23.6) 
22.65 (19.9, 
25.6) 
NA NA 
P10 (%), (95% CI)  19 (15.3-22.4) 24.1 (20.6-
28.2) 
17.7 (14.5-
21.1) 
NA NA 
P30 (%), (95% CI)  47.8 (43.1-
52.2) 
60.1 (56.1-
64.9) 
45 (40.5-49.5) NA NA 
P50 (%), (95% CI)  69.1 (65.3- 80.8 (77.6- 67.8 (63.5- NA NA 
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73.3) 84.4) 72.1) 
 External validation cohort   
Median difference (95% 
CI), ml/minute/1.73 m2 
6.5 (4.9, 8.4) -4.7 (-9.1, 0.5) -22.6 (-27.4, -
16.2) 
-7.0 (-13.0, -
2.1) 
31.0 (24.4, 
35.0) 
16.5 (13.8, 
22.0) 
Interquartile Range for 
differences (95% CI), 
ml/minute/1.73 m2 
10.9 (7.9, 13.3) 23.0 (17.2, 
30.2) 
27.1 (22.5, 
33.4) 
20.0 (17.3, 
27.7) 
25.0 (19.0, 
35.5) 
17.5 (14.3, 
28.1) 
P10 (%), (95% CI) 56.1 (42.2-68.3) 29.3 (18.3-
39.5) 
19.5 (13-30) 31.7 (20.3-
44.5) 
9.8 (3.7-14.6) 15.9 (8.0-25.1) 
P30 (%), (95% CI) 89.0 (80.7-95.7) 75.6 (66.9-86.0 46.3 (36.6-
57.6) 
75.6 (65.3-
84.1) 
26.8 (17.8-
37.1) 
65.9 (56.1-
75.6) 
P50 (%), (95% CI) 98.8 (95.1-
100.0) 
92.7 (86.0-
97.6) 
76.8 (66.7-
87.9) 
89.0 (80.1-
95.0) 
64.6 (53.7-
74.9) 
95.1 (89.0-
98.8) 
 Internal validation cohort   
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Median difference (95% 
CI), ml/minute/1.73 m2 
3.0 (0.4, 6.4) -14.2 (-17.6, -
10.4) 
-10.6 (-13.1, -
9.1) 
-14.9 (-19.0, -
11.7) 
NA NA 
Interquartile Range for 
differences (95% CI), 
ml/minute/1.73 m2 
20.4 (16.7, 24.9) 20.8 (17.6, 
26.1) 
19.0 (15.6, 
23.2) 
21.2 (17.2, 
24.2) 
NA NA 
P10 (%), (95% CI) 45.4 (37.0-54.0) 25.9 (19.9-
32.5) 
28.2 (22.6-
35.1) 
24.1 (17.4-
31.4) 
NA NA 
P30 (%), (95% CI) 88.5 (83.1-93.2) 60.9 (53.8-
69.2) 
70.7 (62.6-
77.6) 
59.2 (51.5-
66.5) 
NA NA 
P50 (%), (95% CI) 96.6 (93.4-98.9) 81.0 (75.0-
88.0) 
85.1 (79.0-
89.8) 
77.0 (69.9-
83.6) 
NA NA 
95%CI: 95% Confidence Interval, MDRD: Modification of Diet in Renal Disease, CKD-EPI: chronic kidney disease–epidemiology, NR: not relevant 
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WEB APPENDIX 
 
Glomerular Filtration Rate Assessment using radioisotope plasma clearance 
This was performed by the methods described by Wickham for the training and internal validation 
cohort. The “slope intercept” method described in the current BNMS Guidelines is based on the 
assumption that from two hours after a bolus injection of tracer the decay of plasma concentration of 
the tracer can be described by a single terminal exponential and so the area under the plasma clearance 
curve can be estimated using measurements of plasma samples taken between two and five hours post 
injection. The presence of ascites means that this is not the case. In order to overcome this limitation, 
Wickham et al have described a modified plasma clearance method for assessment of GFR that can be 
used in liver patients with ascites (1). In thirteen patients with known ascites the plasma clearance was 
fully characterized using up to 16 plasma samples taken between 5 minutes and 24 hours post injection. 
They showed that GFR could be calculated using plasma samples taken at 2, 4, 8, and 24 hours and 
using a log–linear trapezoidal rule with extrapolation to zero and infinity to calculate the area under the 
plasma clearance curve. In a follow-up study to validate the technique they compared this calculation 
with measurements based on urine collection (2). They also showed that for liver transplant candidates 
without ascites, this method showed good agreement with the “slope intercept” technique described in 
the current guidelines with plasma samples taken at 2, 4 and 6 hours post injection. 
Patients were given an intravenous bolus injection of either 2·6 MBq of Cr-51 
ethylenediaminetetraacetic acid (EDTA) (2007 to October 2012) or 9.5 MBq Tc-99m diethylene 
triamine pentaacetic acid (DTPA) (October 2012 to September 2014) in one arm. Biggi et al (3) have 
shown good agreement between clearance of Cr-51 EDTA and Tc-99m DTPA. Blood samples were 
taken from the antecubital vein contralateral to the injected arm at 2, 4, 8 and 24 hours post injection. 
Standard samples and plasma samples were prepared and counted according to the BNMS guidelines 
(4).  
Clearance, CL, was calculated using Eq. (1). 
𝑪𝑪 = 𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨 𝒂𝒂𝑨𝑨𝒂𝑨𝑨𝒂
𝑨𝑨𝑪
 (1), where AUC is the area under the plasma clearance curve given in Eq. 
(2). 
𝐴𝐴𝐴 = ∫ 𝐴(𝑡)𝑑𝑡∝0  (2), where C(t) is the plasma concentration at time t after administration. 
The AUC was calculated using a log-lin trapezoidal method. AUC of plasma concentrations between 
sequential time samples was estimated using exponential function interpolation. AUC before the first 
sample and after the last sample were calculated from exponential function back-extrapolation from the 
first two time samples and from forward extrapolation from the last two time samples. Further details 
of the AUC calculation are given in (1, 2).  Calculation of the normalised GFR included a correction 
for a “fast exponential” as recommended in the current BNMS guidelines (4), and summarised below. 
Clearance values were normalised for body surface area using Eq. (5). CLnorm = CL × 1.73𝐵𝐵𝐵 (5), where CLnorm is the normalised clearance and BSA is body surface area. 
The correction for the fast exponential was applied using Eq. (4). CLcor−norm = 1.0004 × CLnorm − 0.00146 × CLnorm2  (4), where CLcor-norm is the corrected 
normalised clearance. 
 For the internal validation dataset, assessment of GFR using radioisotope plasma clearance 
was carried out using the “slope intercept” method described in (4) with plasma samples taken at 2, 4 
and 6 hours after an intravenous bolus injection of 2·6 MBq of Cr-51 EDTA in patients without ascites. 
For patients with ascites the method of Wickham et al (1, 2) was used. Correction for the “fast 
exponential” and normalisation for BSA were carried out as described above for the training dataset.  
For the external validation set, measurement of GFR was assessed with Cr-51 EDTA  by sampling 
blood, after intravenous injection of tracer over 1-2 minutes, at 2, 4, and 6 hours. 51Chr-GFR was 
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calculated using the slope-intercept technique, correcting for body surface area, and the fast 
exponential curve recommended by the BNMS guidelines (6). 
 
Formulae for Glomerular Filtration Rate Estimation 
The simplified MDRD-4 study equation was calculated as follows: GFR (mL/minute/1·73 m2) = 175 x 
(serum creatinine [mg/dl])-1·154 x (age [year])-0·203 x (0·762 if patient is female) x (1·21 if patient is 
black) (2). The extended MDRD-6 Study equation was calculated as follows: GFR (ml/minute/1·73 
m2) = 0.94086 x 170 x (serum creatinine [mg/dl])-0.999 x (age [year])-0.176 x (0·762 if patient is female) x 
(1·18 if patient is black) x (serum urea nitrogen [mg/dl])-0.170 x (serum albumin [g/dl])0.318 (7). GFR was 
normalised to body surface area (BSA) using the Dubois formula: BSA=0.007184 x W0.425 x H0.725 (9). 
The CKD-EPI equation was calculated as described by Levey et al (5). The CKD-EPI cystatin C and 
the CKD-EPI cystatin C-creatinine equations were calculated as described by Inker et al (10) and 
Stevens et al (11). The MELD score at evaluation was calculated according to the formula of the 
United Network for Organ Sharing available at www.unos.org (12).  
Statistical Analysis 
Descriptive analysis 
Numerical data were expressed as mean±standard deviation if parametric or as median, interquartile 
range (IQR) and range (minimum to maximum) if non-parametric. All variables were tested for normal 
distribution using the Kolmogorov-Smirnov test. Categorical data were expressed as counts and 
percentages. Categorical variables were tested using the chi-square and Fisher’s exact test. Continuous 
variables with and without normal distribution were compared using Student’s t-test or the Mann-
Whitney U test, respectively.  
 Spearman’s correlation coefficient analysis was used for correlation between GFR measured 
with isotope plasma clearance (mGFR) and GFRs as calculated with the different formulae.  Bland and 
Altman plots were used to assess agreement. 
 The MDRD study equation was rearranged to give an expression for creatinine concentration 
in terms of GFR. This expression was used to calculate a value for corrected creatinine concentration 
from mGFR. Subsequently, a corrected MELD was calculated. Wilcoxon signed rank test was used to 
assess the differences between corrected and observed MELD scores. Multivariate binary regression 
analysis (Forward LR method) was used to determine the factors predicting a difference of >20 
ml/min/1·73 m2 between MDRD and mGFR, as well as a difference of ≥3 points between corrected 
and observed MELD. 
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Appendix Figure 1 Bland-Altman plots comparing Glomerular Filtration Rate 
measured using isotope plasma clearance (mGFR) with MDRD-4 (a), CKD-
EPI (b) and RFH cirrhosis GFR (c) formulae for GFR estimation in the 
validation dataset.  
(a) 
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(b) 
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 Appendix Figure 2 Normal probability plot of the difference between 
observed and predicted Glomerular Filtration Rate (GFR) (residuals). The 
residuals follow a straight line indicating that they are normally distributed. 
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Appendix Table 1 Performance of the new equation, MDRD-4 and CKD-EPI in both the training and the validation dataset 
stratified by the degree of liver failure (Child-Pugh class A versus class B versus class C).   
 New equation MDRD-4 CKD-EPI 
Training cohort 
Child-Pugh A (n=115) 
Median difference (95% CI), ml/minute/1.73 m2 2.2 (-1.7, 7.1) -10.5 (-15.7, -9.0) -13.9 (-16.7, -11.3) 
Interquartile Range for differences (95% CI), 
ml/minute/1.73 m2 
18.5 (14.1, 25.3) 21.0 (15.9, 28.6) 19.2 (13.4, 21.3) 
P10 (%), (95% CI) 50.4 (40.9-61.7) 28.7 (19.7-35.3) 25.2 (16.6-34.1) 
P30 (%), (95% CI) 91.3 (83.8-96.4) 66.1 (55.3-75.9) 69.6 (60.9-78.4) 
P50 (%), (95% CI) 97.4 (93.9-100.0) 87.8 (81.3-94.7) 85.2 (76.8-91.5) 
Child-Pugh B (n=242) 
Median difference (95% CI), ml/minute/1.73 m2 0.9 (-2.3, 2.5) -19.9 (-23.3, -17.3) -19.8 (-23.2, -17.8) 
Interquartile Range for differences (95% CI), 
ml/minute/1.73 m2 
17.6 (15.5, 20.8) 21.7 (18.7, 26.0) 21.2 (17.3, 25.7) 
P10 (%), (95% CI) 43.6 (38.6-50.1) 16.9 (13.5-22.9) 17 (12.3-22.7) 
P30 (%), (95% CI) 85.5 (80.2-90.3) 47.1 (39.4-52.5) 41.9 (37.1-49.6) 
P50 (%), (95% CI) 97.1 (94.4-99.2) 67.8 (61.5-73.5) 66.8 (61.1-73.7) 
Child-Pugh C (n=112) 
Median difference (95% CI), ml/minute/1.73 m2 0.05 (-2.7, 2.5) -26.4 (-31.2, -22.5) -28.3 (-33.7, -25.2) 
Interquartile Range for differences (95% CI), 
ml/minute/1.73 m2 
18.5 (13.0, 22.1) 30.7 (24.2, 36.8) 27.5 (19.7, 33.3) 
P10 (%), (95% CI) 40.2 (29.8-49.5) 13.4 (7.0-20.3) 11.6 (4.6-18.0) 
P30 (%), (95% CI) 86.6 (78.8-94.2) 30.4 (20.9-38.6) 26.8 (18.9-34.2) 
P50 (%), (95% CI) 98.2 (95.9-100.0) 52.7 (43.2-62.0) 52.7 (43.5-62.8) 
Validation cohort 
Child-Pugh A (n=65) 
Median difference (95% CI), ml/minute/1.73 m2 5.9 (2.6, 9.0) -9.30 (-12.5, -6.0) -10.4 (-14.5, -7.4) 
Interquartile Range for differences (95% CI), 
ml/minute/1.73 m2 
19.4 (13.3, 26.4) 17.8 (10.7-22.3) 18.2 (12.9, 25.1) 
P10 (%), (95% CI) 47.9 (36.4-62.8) 33.8 (22.0-47.3) 28.2 (19.6-39.8) 
P30 (%), (95% CI) 94.4 (89.1-98.7) 78.9 (68.6-88.9) 77.5 (66.0-87.2) 
P50 (%), (95% CI) 97.2 (93.3-100.0) 91.5 (84.3-97.9) 90.1 (83.3-96.7) 
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Child-Pugh B (n=75) 
Median difference (95% CI), ml/minute/1.73 m2 5.9 (-0.3, 8.7) -13.7 (-17.8, -8.6) -14.1 (-21.7, -11.1) 
Interquartile Range for differences (95% CI), 
ml/minute/1.73 m2 
25.3 (16.9, 29.4) 22.2 (16.9, 31.2) 21.7 (16.7, 32.5) 
P10 (%), (95% CI) 41.5 (32.4-51.9) 26.8 (15.7-38.9) 28.0 (18.1-38.0) 
P30 (%), (95% CI) 89.0 (80.6-96.1) 62.2 (52.2-72.8) 59.8 (45.9-71.5) 
P50 (%), (95% CI) 95.1 (88.9-100.0) 84.1 (75.3-93.6) 79.3 (69.2-87.8) 
Child-Pugh C (n=34) 
Median difference (95% CI), ml/minute/1.73 m2 -1.7 (-7.5, 2.0) -23.5 (-32.7, -17.5) -26.3 (-29.1, -20.9) 
Interquartile Range for differences (95% CI), 
ml/minute/1.73 m2 
15.04 (10.1-23.7) 23.5 (15.9, 44.3) 19.8 (10.5-32.0) 
P10 (%), (95% CI) 45.9 (28.6-60.9) 10.8 (2.6-19.1) 8.1 (0.0-17.8) 
P30 (%), (95% CI) 75.7 (57.9-93.5) 27.0 (12.2-43.1) 27.0 (12.0-40.8) 
P50 (%), (95% CI) 94.6 (88.3-100.0) 56.8 (39.0-74.8) 45.9 (29.6-60.0) 
95%CI: 95% Confidence Interval, MDRD: Modification of Diet in Renal Disease, CKD-EPI: (chronic kidney disease–epidemiology) 
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Appendix Table 2 Performance of the new equation, MDRD-4 and CKD-EPI in both the training and the validation dataset 
stratified by level of measured GFR (≥ 60 or < 60 ml/min/1.73 m2).   
 New equation MDRD-4 CKD-EPI 
Training cohort 
Measured GFR ≥60 ml/min/1.73m2 (n=274) 
Median difference (95% CI), ml/minute/1.73 m2 5.86 (4.00, 8.3) -18.6 (-21.5, -16.1) -16.7 (-19.0, -14.2) 
Interquartile Range for differences (95% CI), 
ml/minute/1.73 m2 
20.7 (16.2, 24.2) 27.3 (23.4, 31.8) 20.2 (17.8, 24.3) 
P10 (%), (95% CI) 42.7 (36.6-48.1) 26.6 (21.0-32.2) 26.3 (20.4-30.8) 
P30 (%), (95% CI) 92.7 (89.7-96.1) 61.3 (55.1-67.1) 64.2 (57.9-69.7) 
P50 (%), (95% CI) 99.6 (98.8-100) 81.4 (76.7-86.3) 85.4 (80.3-89.6) 
Measured GFR <60 ml/min/1.73m2 (n=195) 
Median difference (95% CI), ml/minute/1.73 m2 -3.3 (-4.6, -2.3) -19.7 (-22.7, -15.9) -24.8 (-28.0, -21.2) 
Interquartile Range for differences (95% CI), 
ml/minute/1.73 m2 
11.4 (9.0, 14.4) 21.3 (18.4, 28.4) 23.7 (18.9, 29.2) 
P10 (%), (95% CI) 46.7 (40.1-54.3) 8.2 (4.2-11.3) 5.6 (2.5-9.4) 
P30 (%), (95% CI) 79 (73.1-85.9) 28.7 (21.3-34.0) 17.9 (12.8-23.0) 
P50 (%), (95% CI) 93.8 (90.4-97.4) 51.8 (44.9-58.8) 43 (36.5-50.5) 
Validation cohort 
Measured GFR ≥60 ml/min/1.73m2 (n=123) 
Median difference (95% CI), ml/minute/1.73 m2 8.2 (6.2, 10.8) -12.4 (-16.2, -9.1) -11.7 (-14.8, -9.2) 
Interquartile Range for differences (95% CI), 
ml/minute/1.73 m2 
20.9 (16.1, 26.1) 22.0 (18.6, 28.5) 22.6 (18.9, 27.0) 
P10 (%), (95% CI) 47.4 (38.4-56.4) 32.6 (24.8-42.2) 33.3 (27.4-40.4) 
P30 (%), (95% CI) 94.8 (91.4-98.2) 73.3 (65.4-81.5) 75.6 (68.4-81.3) 
P50 (%), (95% CI) 99.3 (97.4-100) 93.3 (88.4-97.6) 91.9 (86.5-95.3) 
Measured GFR <60 ml/min/1.73m2 (n=51) 
Median difference (95% CI), ml/minute/1.73 m2 -4.5 (-8.6, -1.8) -17.0 (-22.3, -12.0) -21.7 (-26.3, -15.7) 
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Interquartile Range for differences (95% CI), 
ml/minute/1.73 m2 
11.0 (8.3, 17.6) 19.6 (12.2, 27.5) 24.0 (14.5, 30.7) 
P10 (%), (95% CI) 38.2 (23.7-54.4) 10.9 (4.1-20.3) 1.8 (0.0-6.1) 
P30 (%), (95% CI) 72.7 (62.5-87.1) 32.7 (18.0-43.7) 21.8 (10.3-35.4) 
P50 (%), (95% CI) 87.3 (76.8-97) 52.7 (36.7-64.6) 40.0 (24.8-52.3) 
95%CI: 95% Confidence Interval, MDRD: Modification of Diet in Renal Disease, CKD-EPI: (chronic kidney disease–epidemiology) 
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